Navigation Links
Regado Biosciences to Present at the BioPharm America 2009 Conference on September 17, 2009
Date:9/15/2009

BASKING RIDGE, N.J., Sept. 15 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced today that Chris Courts, Vice President, Finance, will be presenting at the BioPharm America Conference 2009 in San Francisco, CA at 3:15 on Thursday, September 17, 2009 (PST). Mr. Courts' presentation will include an overview of the Company's pipeline with emphasis on the lead development program, the anticoagulant system, REG1.

ABOUT REGADO BIOSCIENCES

Regado Biosciences is pioneering a new therapeutic technology with the creation and development of two-component drug systems. Each system comprises a nuclease-stabilized RNA aptamer that can be controlled directly by its specific and complementary oligonucleotide active control agent. This technology is being applied to injectable antithrombotics, including anticoagulants and antiplatelet agents, a multi-billion dollar market in need of therapeutics with improved safety profiles and a greater degree of therapeutic control. Regado's technology is designed to give physicians the ability to actively and directly control each system's therapeutic effect providing a safe and unique approach to personalized medicine.

ABOUT REG1 and REG2

Regado's lead program, the anticoagulant system REG1, consists of two parenteral agents both administered by IV bolus, the first being a potent highly selective Factor IXa inhibitor (RB006) and the second being its complementary active control agent (RB007). RB007 can be used to selectively completely or partially reverse the anticoagulant effect of RB006. REG1 is intended for application in arterial thrombosis applications, initially in Acute Coronary Syndrome patients undergoing Percutaneous Coronary Intervention. REG2, Regado's second product candidate, consists of a subcutaneously administered formulation of RB006 paired with the IV bolus formulation of RB007. REG2 is intended for use in venous thrombosis indications

ABOUT APTAMERS

RB006 is a member of a class of compounds called aptamers. Aptamers are single stranded oligonucleotides that adopt a specific conformation enabling direct, specific inhibition of the targeted protein. A key unique feature of aptamers derives from the fact that they are formed from nucleic acids. As such, their pharmacologic activity can be controlled by a matched, complementary oligonucleotide active control agent (the Watson-Crick base pair complement of a fraction of the agent to be controlled), which can bind to the aptamer, removing it from its target and reversing it biologic effects.

More information can be found at http://www.regadobio.com.


'/>"/>
SOURCE Regado Biosciences
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Regado Biosciences REG1 Anticoagulation System Study Results Published in the Journal of Thrombosis and Haemostasis
2. David J. Mazzo, Ph.D., Joins Regado Biosciences as President and CEO
3. Regado Biosciences to Present at the Piper Jaffray Health Care Conference on Tuesday, December 2, 2008
4. Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer
5. Regado Biosciences To Present at the 27th Annual J.P. Morgan Healthcare Conference
6. Dr. Steven L. Zelenkofske Joins Regado Biosciences as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer
7. Regado Biosciences Establishes Medical Advisory Board
8. Regado Biosciences Expands Medical Advisory Board
9. Regado Biosciences Announces First Patient Enrolled In Phase 1 Study Of Subcutaneously Administered Reg1 Anticoagulation System
10. Regado Biosciences to Present at the Rodman & Renshaw Global Investment Conference on September 10, 2009
11. Regado Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2009 on September 11, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... ... 20, 2017 , ... G&L Scientific Inc, a leading provider ... ), has announced the opening of new offices in Cambridge, Massachusetts, strengthening and ... This is the latest step in G&L’s expansion of its global clinical consulting ...
(Date:1/21/2017)... Jan. 20, 2017 Aratana Therapeutics, Inc. (NASDAQ: ... on the licensing, development and commercialization of innovative biopharmaceutical ... Best Company in North America ... award based on the FDA approval of three ... ENTYCE ® (capromorelin oral solution) and NOCITA ® ...
(Date:1/20/2017)... -- http://www.Financialbuzz.com - According to ... of death worldwide. There were 8.2 million cancer related ... deaths increased gradually over time, the death rates have ... cancers continues to drive demand of biological therapies for ... Insights, Inc. cancer biological therapy market size was USD 61.3 ...
(Date:1/19/2017)... -- WuXi AppTec, a leading global pharmaceutical, biotechnology ... today announced that it has acquired HD Biosciences ... contract research organization (CRO). After completion of acquisition, ... WuXi, and will continue to focus on growing ... acquisition will further strengthen WuXi,s R&D capability from ...
Breaking Biology Technology:
(Date:1/13/2017)... 2017 Sandata Technologies, LLC, a leading ... industry, including Electronic Visit Verification™ (EVV™), announced today ... as Senior Vice President of Product Management. ... homecare experience to Sandata, where he will be ... align Sandata,s suite of solutions with the needs ...
(Date:1/11/2017)... 2017 Intoxalock, a leading ignition interlock provider, ... its patent-pending calibration device. With this new technology, Intoxalock ... upload data logs and process repairs at service center ... "Fighting drunk driving through the application of cutting-edge technologies ... but also for the customer who can get back ...
(Date:1/6/2017)... NEWARK, Calif. , Jan. 5, 2017  Delta ... introduced its iris scanning technology for automotive at CES® ... GNTX ) to demonstrate the use of ... to identify and authenticate the driver in a car, ... automobiles during the driving experience. Delta ID ...
Breaking Biology News(10 mins):